Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor ligand superfamily member 13 (TNFSF13), commonly known as A proliferation-inducing ligand (APRIL), is a cytokine belonging to the tumor necrosis factor (TNF) superfamily. It is primarily expressed by myeloid cells, such as macrophages and dendritic cells, and undergoes proteolytic cleavage by furin to release a biologically active soluble homotrimer. APRIL plays a critical role in humoral immunity by binding to two key receptors: transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). This interaction triggers downstream signaling pathways, such as NF-κB, which are essential for B-cell survival, plasma cell maintenance, and immunoglobulin class switching (particularly to IgA).
Dysregulation and overexpression of APRIL are heavily implicated in the pathogenesis of autoimmune diseases, most notably IgA nephropathy (IgAN), where it drives the overproduction of galactose-deficient IgA1 (Gd-IgA1). It is also associated with systemic lupus erythematosus (SLE), rheumatoid arthritis, and B-cell malignancies like multiple myeloma. Consequently, APRIL has emerged as a major therapeutic target. Biologics targeting this pathway include selective monoclonal antibodies like sibeprenlimab and zigakibart, as well as dual APRIL/BAFF inhibitors like atacicept, telitacicept, and povetacicept. These therapies aim to reduce pathogenic antibody production, alleviate proteinuria, and preserve kidney function, though they carry risks of infection and hypogammaglobulinemia due to systemic B-cell suppression.
Inhibition of APRIL (TNFSF13) binding to its receptors TACI (TNFRSF13B) and BCMA (TNFRSF17), thereby preventing downstream signaling pathways (such as NF-κB) that promote B-cell survival, plasma cell maintenance, and immunoglobulin class switching.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor ligand superfamily member 13 (APRIL) (APRIL).